← United States · All US Insider Profiles

US INSIDER PROFILE · NON-SCORING RESEARCH

Trieu Vuong

Chief Executive Officer

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001587074

Purchase history

Companies traded
1
Purchases · 12M
3
Purchases · 24M
6
Average purchase
$9.7K
Median purchase
$10.0K
Gross purchase value
$58.1K

Companies: Oncotelic Therapeutics, Inc.

6 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

PublishedCompanyTickerRoleReported valueSEC source
2026-07-02Oncotelic Therapeutics, Inc.OTLCChief Executive Officer$9.6KOpen filing
2026-06-24Oncotelic Therapeutics, Inc.OTLCChief Executive Officer$12.8KOpen filing
2026-06-17Oncotelic Therapeutics, Inc.OTLCChief Executive Officer$14.4KOpen filing
2025-07-10Oncotelic Therapeutics, Inc.OTLCChief Executive Officer$2.0KOpen filing
2025-01-31Oncotelic Therapeutics, Inc.OTLCChief Executive Officer$10.4KOpen filing
2024-11-26Oncotelic Therapeutics, Inc.OTLCChief Executive Officer$9.0KOpen filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

No completed point-in-time price outcome is available yet.

Research patterns

First purchase in 12M
0/5
Large purchase ≥ $100k
0/6
Cluster buying · 15D
2/6
Buying the dip
0/—

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.